These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 17654661)
1. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Kalac M; Quintás-Cardama A; Vrhovac R; Kantarjian H; Verstovsek S Cancer; 2007 Sep; 110(5):955-64. PubMed ID: 17654661 [TBL] [Abstract][Full Text] [Related]
2. Response to imatinib mesylate in patients with hypereosinophilic syndrome. Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes. Helbig G; Kyrcz-Krzemień S Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698 [TBL] [Abstract][Full Text] [Related]
4. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Tefferi A; Gotlib J; Pardanani A Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713 [TBL] [Abstract][Full Text] [Related]
5. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Pardanani A; Tefferi A Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941 [TBL] [Abstract][Full Text] [Related]
6. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. Ogbogu PU; Bochner BS; Butterfield JH; Gleich GJ; Huss-Marp J; Kahn JE; Leiferman KM; Nutman TB; Pfab F; Ring J; Rothenberg ME; Roufosse F; Sajous MH; Sheikh J; Simon D; Simon HU; Stein ML; Wardlaw A; Weller PF; Klion AD J Allergy Clin Immunol; 2009 Dec; 124(6):1319-25.e3. PubMed ID: 19910029 [TBL] [Abstract][Full Text] [Related]
7. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome]. Menif S; Ben Romdhane N; Hafsia R Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706 [TBL] [Abstract][Full Text] [Related]
8. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979 [TBL] [Abstract][Full Text] [Related]
9. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Coutré S; Gotlib J Semin Cancer Biol; 2004 Feb; 14(1):23-31. PubMed ID: 14757533 [TBL] [Abstract][Full Text] [Related]
11. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome]. Borbényi Z Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304 [TBL] [Abstract][Full Text] [Related]
12. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. Schwartz LB; Sheikh J; Singh A Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230 [TBL] [Abstract][Full Text] [Related]
13. The hypereosinophilic syndromes: current concepts and treatments. Gleich GJ; Leiferman KM Br J Haematol; 2009 May; 145(3):271-85. PubMed ID: 19243381 [TBL] [Abstract][Full Text] [Related]
14. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib]. Li B; Zhang GS; Dai CW; Pei MF Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548 [TBL] [Abstract][Full Text] [Related]
15. [Hypereosinophilic syndrome--recent developments in diagnosis and treatment]. Hellmich B; Holl-Ulrich K; Gross WL Dtsch Med Wochenschr; 2007 Sep; 132(37):1892-6. PubMed ID: 17823882 [TBL] [Abstract][Full Text] [Related]
16. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Klion AD; Noel P; Akin C; Law MA; Gilliland DG; Cools J; Metcalfe DD; Nutman TB Blood; 2003 Jun; 101(12):4660-6. PubMed ID: 12676775 [TBL] [Abstract][Full Text] [Related]
17. [A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib]. Verstappen MC; Mattijssen V; van der Reijden BA; van der Heijden AJ; Wahab PJ; de Vries RA Ned Tijdschr Geneeskd; 2006 May; 150(21):1188-92. PubMed ID: 16768284 [TBL] [Abstract][Full Text] [Related]
18. [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy]. Sekkach Y; Mekouar F; Jira M; Elqatni M; Elomri N; Fatihi J; Badaoui M; Hammi S; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D Ann Pharm Fr; 2011 Sep; 69(5):277-81. PubMed ID: 21924129 [TBL] [Abstract][Full Text] [Related]
19. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Coutré S; Gotlib J Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431 [TBL] [Abstract][Full Text] [Related]
20. The results of imatinib therapy for patients with primary eosinophilic disorders. Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506 [No Abstract] [Full Text] [Related] [Next] [New Search]